Renal Denervation Highlights: Results of Symplicity HTN-3

TCTAP 2014 Seoul, S. Korea

Krishna Rocha-Singh, MD, FACC Prairie Heart Institute Springfield, IL



the second second





Background




- Due to aging of the population and greater trends towa rds obesity, hypertension is growing in prevalence worldwide.
- Approximately 10% of patients with diagnosed hypertension have "resistant" hypertension.
- The sympathetic nervous system appears to play an important role in resistant hypertension.
- Prior non-blinded studies have suggested that catheter
 -based renal artery denervation reduces blood
 pressure in resistant hypertension.





OBP Response to RDN: Symplicity HTN-1 Three-Yr Follow-up





Too good to be true?

COLLEGE MEDICINE

ASAN Medical Center

SYMPLICITY HTN-1 % Responders Over Time (All Patients)






Trial Objectives




- SYMPLICITY HTN-3 is the first prospective, multi-center, randomized, blinded, sham control led study to evaluate both the safety and efficacy of percutaneous renal artery denervation in patients with severe treatmentresistant hypertension.
- The trial included 535 patients enrolled by 88 participating US centers.

Bhatt DL, Kandzari DE, O'Neill WW, et al...Bakris GL. N Engl J Med 2014







- all blinded to treatment status
- No changes in medications for 6 M







Patient Disposition



1441 subjects assessed for eligibility






	Renal Denervation	Sham Procedure	Difference [95%	
	(N=364)	(N=171)	CI]	P *
MAE	1.4% (5/361)	0.6% (1/171)	0.8% [-0.9%, 2.5	0.67
			%]	


*comparison of MAE to control group

Bhatt DL, Kandzari DE, O'Neill WW, et al...Bakris GL. N Engl J Med 2014





*P value for superiority with a 5 mm Hg margin; bars denote standard deviations



*P value for superiority with a 2 mm Hg margin; bars denote standard deviations

Change in Office SBP by Tertiles of Baseline Office SBP

<170 mm Hg 170 – 184 mm Hg >184 mm Hg 0 N=124 N=54 N=107 N=119 N=54 N=61 △ Office SBP (mm Hg) -4.5 -6.6 -10 -9.8 **P=0.57** -13.8 **P=0.29** -20 -19.7 Denervation -25.7 **Control P=0.13** -30

TCTAP 2014

and the second s

UNIVERSITY OF ULSA COLLEGE MEDICINE



Potential Limitations




- Drug adherence not measured by blood levels, but adherence was measured by patient diaries at baseline and 6 months.
- Medication changes did occur, but results unchanged even when these patients were censored.
- Duration of primary endpoint may have been too short, but prior studies had found benefit by 6 months.
- Operator learning curve is always a possibility, but we found no relationship with procedural volume in the trial.
- Biological confirmation of denervation did not occur, as there is no accepted measure, but appropriate energy delivery was confirmed.







Why Did Symplicity HTN-3 Fail?





UNIVERSITY OF ULSAN

ASAN Medical Center

Symplicity HTN-3 Conclusions



- In a prospective, multicenter, randomized, blinded, sham controlled trial of patients with uncontrolled resistant hypertension, percutaneous renal denervation was safe but not associated with significant additional reductions in office or ambulatory blood pressure.
- These results underscore the importance of blinding and sham controls in evaluations of new devices.
- Further study in rigorously designed clinical trials will be necessary to confirm previously reported benefits of renal denervation in patients with resistant hypertension or to validate alternate methods of renal denervation.





My Personal Take-Aways Clinical Study

- If results looks to good to be true...
- Was the translational model correct?
 Do renal pig arteries = renal anatomy in elderly patients with possible circumferential atherosclerosis?
- Beware of the sham!
- Managing patient behavior + compliance is substantial variable and difficult to control
- We need to shine the light on the RDN
 procedure